Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

µ§Å» ÇÁ¸®½ºÄÉÀÏ·Î Æò°¡ÇÑ º¸Åø¸®´® AÇü µ¶¼Ò ¹Ýº¹ ÁÖ»ç ÈÄ ±ÙÀ°ÀÇ ¾àÈ­

Muscle Weakness after Repeated Injection of Botulinum Toxin Type A Evaluated by Dental Prescale.

±¸°­È¸º¹ÀÀ¿ë°úÇÐÁö 2010³â 26±Ç 1È£ p.69 ~ 75
º¯¿µ¼·, ¼ÛÁöÈñ, ÃÖ¿µÂù, ±è¼ºÅÃ,
¼Ò¼Ó »ó¼¼Á¤º¸
º¯¿µ¼· ( Byun Young-Sub ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç
¼ÛÁöÈñ ( Song Ji-Hee ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç
ÃÖ¿µÂù ( Choi Young-Chan ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç
±è¼ºÅà( Kim Seong-Taek ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç

Abstract

AÇü º¸Åø¸®´® µ¶¼Ò(botulinum toxin type A, BTX-A)´Â ±³±Ù ºñ´ëÀÇ Ä¡·á¿¡ ¼º°øÀûÀ¸·Î Àû¿ëµÇ¾î ¿ÔÁö¸¸ ÁÖ»çºÎÀ§ ±ÙÀ°ÀÇ ¾àÈ­¸¦ ÃÊ·¡ÇÑ´Ù. ÀÌ ¿¬±¸´Â BTX-A¸¦ »ç¶÷ ±³±Ù¿¡ ÁÖ»çÇÑ ÈÄ ÃÖ´ë ±³ÇÕ·Â(Maximum Bite Force, MBF)ÀÇ º¯È­¸¦ ÃøÁ¤ÇÏ°í, ¹Ýº¹ ÁÖ»çÀÇ È¿°ú¸¦ Æò°¡Çϱâ À§ÇØ ½ÃÇàµÇ¾ú´Ù. 30¸íÀÇ ÀÚ¿øÀÚµéÀ» 18ÁÖ°£ ÃßÀû °üÂûÇÏ°í, ÃÖ´ë ±³ÇÕ·ÂÀ» ÃøÁ¤ÇÏ¿´´Ù. 1Â÷ ÁÖ»ç·ÎºÎÅÍ 18ÁÖ°¡ °æ°úÇÑ ÈÄ ½Ã¼ú¿¡ ¸¸Á·ÇÑ 16¸íÀº Á¦¿ÜÇÏ°í ³ª¸ÓÁö 14¸í¿¡°Ô ¹Ýº¹ Áֻ縦 ½ÃÇàÇÏ¿´°í, ´Ù½Ã 18ÁÖ°£ ÃøÁ¤ÇÏ¿´´Ù. Æò±Õ ÃÖ´ë ±³ÇÕ·ÂÀº ÁÖ»ç 2ÁÖ ÈÄ 20% °¨¼ÒÇÏ¿´´Ù°¡ 4ÁÖºÎÅÍ Á¡Â÷ ȸº¹µÇ¾úÀ¸¸ç, 12ÁÖ µÚ¿¡´Â ÁÖ»ç ÀÌÀü ¼öÁØÀ¸·Î ȸº¹µÇ¾ú´Ù. ÃÖ´ë ±³ÇÕ·ÂÀº ÁÖ»ç Àü°ú ÁÖ»ç 2ÁÖ, 4ÁÖ, 8ÁÖÈÄ¿¡¼­ À¯ÀÇÇÑ Â÷À̸¦ º¸¿´´Ù(p<.05). ¹Ýº¹ Áֻ籺(n=14)ÀÇ ÃÖ´ë ±³ÇÕ·ÂÀº 6ÁÖ¿¡ µÎµå·¯Áø °¨¼Ò¸¦ º¸¿´´Ù°¡(p<.05) 12ÁÖ°£ Á¡Â÷ ȸº¹µÇ¾ú´Ù. ½ÇÇ豺ÀÌ °æÇèÇÑ ºÒÆí°¨ÀÇ ¼öÁØÀº ÀϹÝÀûÀÎ ÀúÀÛ¿¡´Â °ÅÀÇ ¿µÇâÀ» ¹ÌÄ¡Áö ¾Ê¾Ò´Ù.

Botulinum toxin type A(BTX-A) has been applied successfully to treat masseteric hypertrophy. However it can cause
muscle weakness. This study was designed to measure the change in maximum bite force(MBF) after BTX-A injection
into human masseter muscle and to evaluate the influence of a booster(repeated) injection. Thirty volunteers completed
18-week follow-up and MBF was measured. At 18 weeks after the first injection, a booster injection was given to 14
patients and they were followed up until 18 weeks from the booster injection. The mean MBF was approximately 20%
lower at 2 weeks than before the injection, and it recovered gradually after 4 weeks to return to the preinjection level at
12 weeks. The MBF differed significantly between before the injection and at 2, 4, and 8 weeks after the injection(p<0.05).
In booster injection group(n=14),the MBF decreased markedly at 6 weeks(p<0.05),and it recovered gradually in 12 weeks.
The MBF was significantly reduced after booster injection of BTX-A into the human masseter muscle. The degree of
discomfort experienced by the subjects had little effect on normal mastication.

Å°¿öµå

±ÙÀ°¾àÈ­;º¸Åø¸®´® AÇü µ¶¼Ò;±³±Ù;¹Ýº¹ ÁÖ»ç
muscle weakness;botulinum toxin type A;masseter muscle;booster injection

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI